S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
S&P 500   3,204.45 (-0.69%)
DOW   26,742.86 (-0.47%)
QQQ   256.55 (-1.67%)
AAPL   384.99 (-1.51%)
MSFT   203.57 (-2.15%)
FB   238.54 (-0.72%)
GOOGL   1,499.87 (-1.12%)
AMZN   2,956.00 (-1.76%)
NVDA   399.91 (-2.24%)
CGC   17.90 (-1.38%)
BABA   242.46 (-2.71%)
MU   49.84 (-1.33%)
GE   7.16 (+0.28%)
TSLA   1,484.06 (-4.01%)
AMD   54.19 (-2.08%)
T   30.38 (+1.23%)
ACB   12.17 (-5.44%)
F   6.83 (+1.34%)
GILD   75.77 (-1.16%)
DIS   119.11 (-1.48%)
NFLX   514.57 (-1.66%)
BAC   24.00 (-2.44%)
BA   180.77 (-3.82%)
Log in

NASDAQ:MBRXMoleculin Biotech Stock Price, Forecast & News

$1.06
-0.02 (-1.40 %)
(As of 07/16/2020 11:51 AM ET)
Add
Compare
Today's Range
$0.95
Now: $1.06
$1.07
50-Day Range
$0.80
MA: $1.02
$1.17
52-Week Range
$0.32
Now: $1.06
$1.97
Volume59,392 shs
Average Volume961,150 shs
Market Capitalization$63.72 million
P/E RatioN/A
Dividend YieldN/A
Beta2.39
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia (AML). The company also develops WP1066 Portfolio, an immuno-stimulating STAT3 inhibitor for the treatment of brain tumors, pancreatic cancer, and AML; and WP1122 Portfolio and related molecules for the treatment of glioblastoma multiforme and related central nervous system malignancies. It also engages in the preclinical development of other drug candidates, including other STAT3 inhibitors and compounds targeting the metabolism of tumors. The company also has a strategic collaboration with the University of Bergen to develop immune stimulation drug; and the Emory University to enable expanded cancer research on WP1066 molecule for the treatment of medulloblastoma, a pediatric malignant primary brain tumor. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
Read More
Moleculin Biotech logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MBRX
CUSIPN/A
Phone713-300-5160

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.34 per share

Profitability

Net Income$-13,200,000.00

Miscellaneous

Employees9
Market Cap$63.72 million
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive MBRX News and Ratings via Email

Sign-up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter.

Moleculin Biotech (NASDAQ:MBRX) Frequently Asked Questions

How has Moleculin Biotech's stock been impacted by COVID-19 (Coronavirus)?

Moleculin Biotech's stock was trading at $0.5051 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MBRX stock has increased by 108.9% and is now trading at $1.0550. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Moleculin Biotech?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Moleculin Biotech in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Moleculin Biotech.

When is Moleculin Biotech's next earnings date?

Moleculin Biotech is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for Moleculin Biotech.

How were Moleculin Biotech's earnings last quarter?

Moleculin Biotech Inc (NASDAQ:MBRX) posted its quarterly earnings results on Monday, May, 11th. The company reported ($0.10) earnings per share (EPS) for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.10). View Moleculin Biotech's earnings history.

What price target have analysts set for MBRX?

3 brokerages have issued 12-month target prices for Moleculin Biotech's shares. Their forecasts range from $2.00 to $3.00. On average, they anticipate Moleculin Biotech's share price to reach $2.50 in the next year. This suggests a possible upside of 137.0% from the stock's current price. View analysts' price targets for Moleculin Biotech.

Has Moleculin Biotech been receiving favorable news coverage?

News coverage about MBRX stock has been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Moleculin Biotech earned a daily sentiment score of 2.1 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View the latest news about Moleculin Biotech.

Who are some of Moleculin Biotech's key competitors?

What other stocks do shareholders of Moleculin Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), Gilead Sciences (GILD), vTv Therapeutics (VTVT), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Novavax (NVAX), Co-Diagnostics (CODX), Verastem (VSTM) and Exelixis (EXEL).

Who are Moleculin Biotech's key executives?

Moleculin Biotech's management team includes the following people:
  • Mr. Walter V. Klemp, Founder, Chairman, Pres & CEO (Age 59)
  • Mr. Jonathan P. Foster, CFO & Exec. VP (Age 55)
  • Dr. Donald H. Picker, Chief Scientific Officer (Age 73)
  • Dr. Waldemar Priebe, Co-Founder and Chairman of Scientific Advisory Board
  • Dr. Robert C. Shepard, Chief Medical Officer (Age 67)

What is Moleculin Biotech's stock symbol?

Moleculin Biotech trades on the NASDAQ under the ticker symbol "MBRX."

How do I buy shares of Moleculin Biotech?

Shares of MBRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Moleculin Biotech's stock price today?

One share of MBRX stock can currently be purchased for approximately $1.06.

How big of a company is Moleculin Biotech?

Moleculin Biotech has a market capitalization of $63.72 million. The company earns $-13,200,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Moleculin Biotech employs 9 workers across the globe.

What is Moleculin Biotech's official website?

The official website for Moleculin Biotech is www.moleculin.com.

How can I contact Moleculin Biotech?

Moleculin Biotech's mailing address is 5300 MEMORIAL DRIVE SUITE 950, HOUSTON TX, 77007. The company can be reached via phone at 713-300-5160.

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.